<DOC>
	<DOCNO>NCT01222312</DOCNO>
	<brief_summary>The study compare two combination chemotherapy patient advance metastatic NSCLC : 50 % patient treat cisplatin docetaxel , 50 % oxaliplatin docetaxel . cisplatin today standard therapy , toxicity profile often tolerable . Especially elderly patient patient comorbidities , oxaliplatin base chemotherapy may lower toxicity comparable even good response rate .</brief_summary>
	<brief_title>Study Therapy Locally Advanced Metastatic Non Small Cell Lung Cancer ( NSCLC ) With Cisplatin / Docetaxel Oxaliplatin / Docetaxel</brief_title>
	<detailed_description>Cispaltin base chemotherapy standard palliative first-line therapy patient advance metastatic NSCLC . Due contraindication cisplatin , substance use high number patient . Especially elderly patient , patient comorbidities patient reduce general condition , cisplatin therapy often induce intolerable toxicity . Thus , therapy often interrupt finish prematurely . Due favorable toxicity profile , oxaliplatin use also treatment elderly patient patient comorbidities . Based toxicity data phase II study group patient gastric cancer , dosage oxaliplatin/docetaxel adopt actual study . In previous phase II trial , response rate oxaliplatin base combination chemotherapy comparable cisplatin patient metastatic NSCLC . In study analyse , oxaliplatin base combination chemotherapy tolerable toxicity profile comparable even good response rate comparison cisplatin base chemotherapy . 44 patient arm either treat maximum 6 cycle cisplatin/docetaxel maximum 8 cycle oxaliplatin/docetaxel .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>histologically cytologically confirm NSCLC stage IIIB IV . previous chemotherapy metastatic state male female patient age &gt; 18 year ECOG ≤ 2 Leukocytes &gt; 3.000/µl Thrombocytes &gt; 100.000/µl Serum creatinine ≤ 1.25x normal value , Creatinine Clearance &gt; 45 ml/min previous radiation &lt; 25 % bone marrow region allow . Previous radiation whole pelvis allow parallel radiation allow , target lesion outside radiation field write informed consent life expectancy &gt; 3 month hypersensibility Cisplatin , Oxaliplatin Docetaxel Neoadjuvant adjuvant chemotherapy within last 6 month radiation within last 28 day severe systemic comorbidities Cardiomyopathy cardiac insufficiency stage IIIV accord NYHA malignant secondary disease , date back &lt; 5 year ( exception : Insitucarcinoma cervix uterus , adequately treat skin basal cell carcinoma ) brain metastasis severe nonsurgical comorbidities acute infection peripheral polyneuropathy &gt; NCI grade II severe liver dysfunction AST/ALT &gt; 3,5xULN , AP &gt; 6xULN , Bilirubin &gt; 1,5xULN ) participation parallel trial pregnancy lactation reduce hearing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>advanced NSCLC</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>cisplatin</keyword>
	<keyword>docetaxel</keyword>
	<keyword>locally advanced metastatic non small cell lung cancer ( stage IIIB-IV )</keyword>
</DOC>